gilead news - Search News

Gilead Sciences, Leerink

Seeking Alpha on MSN · 2d

Gilead upgraded to outperform by Leerink on PrEP outlook

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for the prevention of HIV infection. Read more here.

Gilead Sciences, Inc. (GILD) Stock Rated Outperform by Leerink Partners

On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $88.16 which represents a slight increase of $1.87 or 2.17% from the prior close of $86.29. The stock opened at $85.

Zacks.com on MSN · 4h

Why Gilead Sciences (GILD) Dipped More Than Broader Market Today

Gilead Sciences (GILD) closed the latest trading day at $87.23, indicating a -1.05% change from the previous session's end. This move lagged the S&P 500's daily loss of 0.92%. Meanwhile, the Dow experienced a drop of 0.

Business Insider · 2d

Gilead upgraded to Outperform from Market Perform at Leerink

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following

Fintel on MSN · 2d

Leerink Partners Upgrades Gilead Sciences (GILD)

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Market Perform to Outperform. Analyst Price Forecast Suggests 3.16% Downside As of September 24,

16h

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Signaturefd LLC

Signaturefd LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.1% in the third ...

Yahoo Finance1d

Gilead and MSD to advance once-weekly HIV treatment to Phase III

Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase II trials, following promising ...

1d

Balanced Outlook on Gilead Sciences Amid Anticipated Anito-cel Trial Results

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...

FierceBiotech2d

Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks, setting stage for pivotal program

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

2don MSN

Calls of the Day: Gilead, Berkshire Hathaway and SLB

Donald Trump showed up for his quick shift at McDonald's in Feasterville ready to take orders at the drive-thru.

5d

Gilead withdraws bladder cancer drug in US after failed trial

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

1d

Morgan Stanley says anito-cel Phase 2 data next catalyst for Gilead, Arcellx

Morgan Stanley notes that Gilead (GILD) and Arcellx’s (ACLX) anito-cel, a BCMA-directed CAR-T therapy in development for relapsed / ...

1d

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...

Gilead Withdraws ADC Trodelvy in Bladder Cancer After Trial Failure

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

Barchart on MSN1d

Gilead Sciences’ Quarterly Earnings Preview: What You Need to Know

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results